bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Tables from Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis
Authors: Rajamanickam Subapriya , Panneerdoss Subbarayalu , Gorthi Aparna , Timilsina Santosh , Onyeagucha Benjamin , Kovalskyy Dmytro , Ivanov Dmitri , Hanes Martha A. , Vadlamudi Ratna K. , Chen Yidong , Bishop Alexander J. , Arbiser Jack L. , Rao Manjeet K.
Published: April 2023

Supplementary Table S1: Primers used in the present investigation. Supplementary Table S 2 : Gene Ontology Enrichment Analysis on differentially expressed genes in IB-treated compared to vehicle-treated breast cancer cells using Database for Annotation, Visualization and Integrated Discovery (DAVID). BP- Biological Processes.
Supplementary Figure S3 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Authors: Ota Keiichi , Azuma Koichi , Kawahara Akihiko , Hattori Satoshi , Iwama Eiji , Tanizaki Junko , Harada Taishi , Matsumoto Koichiro , Takayama Koichi , Takamori Shinzo , Kage Masayoshi , Hoshino Tomoaki , Nakanishi Yoichi , Okamoto Isamu
Published: April 2023

Supplementary Figure S3. Effects of AKT and ERK depletion on PD-L1 expression in EML4-ALK fusion-positive (H3122) cells.
Supplementary Table 3 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Authors: Azad Arun A. , Volik Stanislav V. , Wyatt Alexander W. , Haegert Anne , Le Bihan Stephane , Bell Robert H. , Anderson Shawn A. , McConeghy Brian , Shukin Robert , Bazov Jenny , Youngren Jack , Paris Pamela , Thomas George , Small Eric J. , Wang Yuzhuo , Gleave Martin E. , Collins Colin C. , Chi Kim N.
Published: April 2023

Supplementary Table 3. Univariate analysis examining association between baseline clinico-pathological factors and presence of tumour-derived cell-free DNA
supplemental figure legend from The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer
Authors: Lennartz Maximilian , Minner Sarah , Brasch Sophie , Wittmann Hilko , Paterna Leonard , Angermeier Katja , Öztürk Eray , Shihada Rami , Ruge Mingu , Kluth Martina , Koop Christina , Wilczak Waldemar , Krech Till , Lebok Patrick , Wittmer Corinna , Heinzer Hans , Steuber Thomas , Adam Meike , Huland Hartwig , Graefen Markus , Haese Alexander , Simon Ronald , Sauter Guido , Schlomm Thorsten
Published: April 2023

supplemental figure legend
Supplementary Figure S2 from Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
Authors: Iasonos Alexia , Chapman Paul B. , Satagopan Jaya M.
Published: April 2023

Kaplan-Meier curves for progression-free survival in the intention-to-treat population (Panel A); among patients with tumors that were positive for the programmed death 1 ligand (PD-L1) (Panel B) and among patients with PD-L1-negative tumors (Panel C)
Supplementary Figure S1 from Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
Authors: Iasonos Alexia , Chapman Paul B. , Satagopan Jaya M.
Published: April 2023

Progression-free survival according to treatment
Supplementary Tables S1-3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Authors: Brown Christine E. , Badie Behnam , Barish Michael E. , Weng Lihong , Ostberg Julie R. , Chang Wen-Chung , Naranjo Araceli , Starr Renate , Wagner Jamie , Wright Christine , Zhai Yubo , Bading James R. , Ressler Julie A. , Portnow Jana , D'Apuzzo Massimo , Forman Stephen J. , Jensen Michael C.
Published: April 2023

Supplementary Tables S1-3. Table S1. T cell Product Release Criteria. Table S2. Manufacturing Feasibility. Table S3. Characteristics of Patients Who Received Study Treatment.
Supplementary Figure 2 from Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia
Authors: Yamada Atsushi , Horimatsu Takahiro , Okugawa Yoshinaga , Nishida Naoshi , Honjo Hajime , Ida Hiroshi , Kou Tadayuki , Kusaka Toshihiro , Sasaki Yu , Yagi Makato , Higurashi Takuma , Yukawa Norio , Amanuma Yusuke , Kikuchi Osamu , Muto Manabu , Ueno Yoshiyuki , Nakajima Atsushi , Chiba Tsutomu , Boland C. Richard , Goel Ajay
Published: April 2023

Supplementary figure 2: Kaplan Meier survival curves based upon expression levels of miR-21, miR-29a, miR-125b and their combination, when comparing patients with colorectal neoplasms (CRN) with healthy controls (HC), and when comparing patients with advanced neoplasms (AN) with patients without advanced neoplasms (non-AN), after exclusion of all patients with colorectal cancer.
Supplemental Figure 2 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
Authors: Karjalainen Katja , Jaalouk Diana E. , Bueso-Ramos Carlos , Bover Laura , Sun Yan , Kuniyasu Akihiko , Driessen Wouter H.P. , Cardó-Vila Marina , Rietz Cecilia , Zurita Amado J. , O'Brien Susan , Kantarjian Hagop M. , Cortes Jorge E. , Calin George A. , Koivunen Erkki , Arap Wadih , Pasqualini Renata
Published: April 2023

Supplemental Figure 2. Cell membrane and cytoplasmic expression of IL-11R.
Video 2 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Authors: Lehmann Steffi , Perera Ramanil , Grimm Hans-Peter , Sam Johannes , Colombetti Sara , Fauti Tanja , Fahrni Linda , Schaller Teilo , Freimoser-Grundschober Anne , Zielonka Jörg , Stoma Szymon , Rudin Markus , Klein Christian , Umana Pablo , Gerdes Christian , Bacac Marina
Published: April 2023

In vitro live cell epifluorescence imaging of LS174T RFP cells co-cultured with non-labeled human T-cells (E:T=3:1) in the presence of CEA or a control TCB, respectively. Apoptosis is visualized (in green) through addition of a nuclear caspase probe (Cell Event Caspase 3/7 green Detection reagent).
Supplemental Figure 2 from T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Authors: Kong Yaxian , Zhu Liuluan , Schell Todd D. , Zhang Jianhong , Claxton David F. , Ehmann W. Christopher , Rybka Witold B. , George Melissa R. , Zeng Hui , Zheng Hong
Published: April 2023

TIGIT+ CD8+ T cells from AML patients retain capacity of proliferation and cytotoxicity.
Supplementary Tables S1-S4 and Figures S1-S3 from Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Authors: Tolcher Anthony W. , Khan Khurum , Ong Michael , Banerji Udai , Papadimitrakopoulou Vassiliki , Gandara David R. , Patnaik Amita , Baird Richard D. , Olmos David , Garrett Christopher R. , Skolnik Jeffrey M. , Rubin Eric H. , Smith Paul D. , Huang Pearl , Learoyd Maria , Shannon Keith A. , Morosky Anne , Tetteh Ernestina , Jou Ying-Ming , Papadopoulos Kyriakos P. , Moreno Victor , Kaiser Brianne , Yap Timothy A. , Yan Li , de Bono Johann S.
Published: April 2023

Supplementary Tables S1-S4 and Figures S1-S3. Tables S1/S2: % tumor response in mice with HCT116 and A2058 tumor xenografts following treatment; Table S3: Diagram showing dose-decision guidelines utilized in the MK-2206 clinical study based on observed toxicities; Table S4: number of patients with drug-related AEs in all courses of treatment; Figure S1/S2: Line graph showing the relative tumor volume and body weight observed in patients over time expressed in terms of days following treatment; Figure S3: Patient presenting with Grade III rash
Supplementary Figure S2 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Authors: Klintman Marie , Buus Richard , Cheang Maggie Chon U. , Sheri Amna , Smith Ian E. , Dowsett Mitch
Published: April 2023

Correlation coefficient matrix between of genes and IHC ER, PgR, and Ki67. Shades of blue indicate a positive correlation, and shades of orange a negative correlation.
Supplementary Materials and Methods, Supplementary Figure 1-6 Legends from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Materials and Methods, Supplementary Figure 1-6 Legends. Materials and Methods, References, Figure 1-6 Legends
Supplementary Figure S4. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Authors: Chen Eddy J. , Sowalsky Adam G. , Gao Shuai , Cai Changmeng , Voznesensky Olga , Schaefer Rachel , Loda Massimo , True Lawrence D. , Ye Huihui , Troncoso Patricia , Lis Rosina L. , Kantoff Philip W. , Montgomery Robert B. , Nelson Peter S. , Bubley Glenn J. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Supplementary Figure S4. AR antagonist activities of dutasteride versus bicalutamide in LAPC4 cells.
Figure S6 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
Authors: Göke Friederike , Franzen Alina , Hinz Trista K. , Marek Lindsay A. , Yoon Petros , Sharma Rakesh , Bode Maike , von Maessenhausen Anne , Lankat-Buttgereit Brigitte , Göke Antonia , Golletz Carsten , Kirsten Robert , Boehm Diana , Vogel Wenzel , Kleczko Emily K. , Eagles Justin R. , Hirsch Fred R. , Van Bremen Tobias , Bootz Friedrich , Schroeck Andreas , Kim Jihye , Tan Aik-Choon , Jimeno Antonio , Heasley Lynn E. , Perner Sven
Published: April 2023

Figure S6. Correlation of HPV-expression and FGFR1 mRNA expression.
Supplementary Table S1 from Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Authors: Bonito Nair A. , Borley Jane , Wilhelm-Benartzi Charlotte S. , Ghaem-Maghami Sadaf , Brown Robert
Published: April 2023

Clinical characteristics for Hammersmith Hospital (HH) and The Cancer Genome Atlas (TCGA) datasets.
Figure S3 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
Authors: Göke Friederike , Franzen Alina , Hinz Trista K. , Marek Lindsay A. , Yoon Petros , Sharma Rakesh , Bode Maike , von Maessenhausen Anne , Lankat-Buttgereit Brigitte , Göke Antonia , Golletz Carsten , Kirsten Robert , Boehm Diana , Vogel Wenzel , Kleczko Emily K. , Eagles Justin R. , Hirsch Fred R. , Van Bremen Tobias , Bootz Friedrich , Schroeck Andreas , Kim Jihye , Tan Aik-Choon , Jimeno Antonio , Heasley Lynn E. , Perner Sven
Published: April 2023

Figure S3. Correlation of FGFR1 mRNA and protein expression with BGJ398 sensitivity.
Supplementary Information from SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Authors: Piccione Emily C. , Juarez Silvia , Tseng Serena , Liu Jie , Stafford Melissa , Narayanan Cyndhavi , Wang Lijuan , Weiskopf Kipp , Majeti Ravindra
Published: April 2023

Supplementary Figure Legends
SUPPLEMENTARY DATA from PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Authors: Sabbatino Francesco , Villani Vincenzo , Yearley Jennifer H. , Deshpande Vikram , Cai Lei , Konstantinidis Ioannis T. , Moon Christina , Nota Sjoerd , Wang Yangyang , Al-Sukaini Ahmad , Zhu Andrew X. , Goyal Lipika , Ting David T. , Bardeesy Nabeel , Hong Theodore S. , Fernandez-del Castillo Carlos , Tanabe Kenneth K. , Lillemoe Keith D. , Ferrone Soldano , Ferrone Cristina R.
Published: April 2023

SUPPLEMENTARY MATERIALS AND METHODS
Figure S2 from SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Authors: Piccione Emily C. , Juarez Silvia , Tseng Serena , Liu Jie , Stafford Melissa , Narayanan Cyndhavi , Wang Lijuan , Weiskopf Kipp , Majeti Ravindra
Published: April 2023

Supplementary Figure S2: SIRPabodies bind to CD20 and CD47 on dual antigen-expressing tumor cells
SUPPLEMENTARY DATA from PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Authors: Sabbatino Francesco , Villani Vincenzo , Yearley Jennifer H. , Deshpande Vikram , Cai Lei , Konstantinidis Ioannis T. , Moon Christina , Nota Sjoerd , Wang Yangyang , Al-Sukaini Ahmad , Zhu Andrew X. , Goyal Lipika , Ting David T. , Bardeesy Nabeel , Hong Theodore S. , Fernandez-del Castillo Carlos , Tanabe Kenneth K. , Lillemoe Keith D. , Ferrone Soldano , Ferrone Cristina R.
Published: April 2023

Figure S1. Representative staining patterns of formalin-fixed, paraffinembedded primary ICC lesions with nitrotyrosine-specific mAb.
Supplementary Figures 1-10 from Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6
Authors: Sun Hongcheng , Tang Huamei , Xie Dacheng , Jia Zhiliang , Ma Zhenyu , Wei Daoyan , Mishra Lopa , Gao Yong , Zheng Shaojiang , Xie Keping , Peng Zhihai
Published: April 2023

Supplementary Fig. S1. KLF4 protein expression in human HCC specimens and its association with tumor grade. Supplementary Fig. S2. KLF4 protein expression in human HCC and paired nontumor tissue specimens. Supplementary Fig. S3. Expression of differentiation-associated markers in microdissected well-differentiated (grade 1) and poorly differentiated (grade 3) HCC cells in frozen tissue sesctions. Supplementary Fig. S4. Characterization of ZFD-deleted KLF4 protein (KLF4 ZFD). Supplementary Fig. S5. The influence of treatment with sodium butyrate on the expression of LETFs and KLF4. Supplementary Fig. S6. HNF-6 and KLF4 protein expression in human HCC specimens and their association with tumor grade. Supplementary Fig. S7. Alb-Cremediated KLF4 deletion in the murine liver. Supplementary Fig. S8. Basic activity of HNF-6 promoter reporters in HCC cells. Supplementary Fig. S9. Endogenous binding of KLF4 to the HNF-6 promoter. Supplementary Fig. S10. Prognostic significance of KLF4 and HNF-6 expression in HCC patients after OLT.
Supplementary Table 1 from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplementary Table 1. Clinical Characteristics of PDA specimens.
Supplementary Figure legends from Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6
Authors: Sun Hongcheng , Tang Huamei , Xie Dacheng , Jia Zhiliang , Ma Zhenyu , Wei Daoyan , Mishra Lopa , Gao Yong , Zheng Shaojiang , Xie Keping , Peng Zhihai
Published: April 2023

Supplementary Figure legends
Supplementary Figure 6. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

BET inhibition preferentially disrupts expression of genes associated with super-enhancers. (a) ChIP-seq profiles for H3K27Ac binding at representative super-enhancer-associated gene loci, including MYCN, NCOR2, BCOR and GLI2, in MYCN-amplified IMR-5 cells. The x-axis shows genomic position and the y-axis the histone mark signal in units of reads per million per base pair (rpm/bp). The gene model is depicted below and scale bars above the binding profiles. (b) The Fisher exact test shows enrichment of super-enhancer associated genes among the downregulated genes (logFC < 0 and q < 0.05) by OTX015 or JQ1 treatment. (c) Cumulative distribution plots of the top 200 super-enhancer-associated genes and their fold-change measured using genes which are differentially regulated in IMR-5 cells by OTX015 treatment, JQ1 treatment or the overlap between these datasets (left to right). Plots show a shift towards negative logFC for super-enhancer associated genes (blue curves) compared to genes not associated with super-enhancers (black curves). (d) Box plots of log2-fold changes in the top 200 genes associated with super-enhancers (SE) and regular enhancers (non-SE) in genes differentially regulated (compared to DMSO-treated controls) in IMR-5 cells treated with OTX015, JQ1 or the overlap from both datasets (left to right). Statistical significance was determined using a two-sided Mann-Whitney test.
Supplementary Figure 2 from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplementary Figure 2. Detection of extracellular TG2.
Supplementary Figure 1 from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplementary Figure 1. Enzymatic activity of TG2 in PDA cells.
MYCN targets OTX015_BRD4 and gene expression from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

Westermann et al. as well as Valentijn et al. MYCN target gene list and expression changes after OTX015 treatment as well as BRD4 binding
Supplementary Figure Legends from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Authors: Groeneweg Jolijn W. , Hernandez Silvia F. , Byron Virginia F. , DiGloria Celeste M. , Lopez Hector , Scialabba Vanessa , Kim Minji , Zhang Ling , Borger Darrell R. , Tambouret Rosemary , Foster Rosemary , Rueda Bo R. , Growdon Whitfield B.
Published: April 2023

Supplementary Figure Legends. The supplementary figure legends are in this document as requested.
IMR5_H3K27ac_AllnonPromoterPeaks from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

All H3K27Ac peaks called in non-promoter regions in IMR5
GSEA general cell biology gene sets from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

GSEA of gene sets describing general cellular processes after treatment with OTX015 and/or JQ1(GSEA, Broad institute)
GSEA cancer gene sets OTX015 and JQ1 from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

GSEA of cancer gene sets after treatment with OTX015 and/or JQ1(GSEA, Broad institute)
Differentially expressed genes OTX015 JQ1 from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

Differentially expressed genes in IMR5 cells after OTX015 and JQ1 treatment respectively
Supplementary Figures 1-4 and Tables 1-4 from Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells
Authors: Zhang Wei , Yi Bin , Wang Chao , Chen Dongquan , Bae Sejong , Wei Shi , Guo Rong-Jun , Lu Changming , Nguyen Lisa L.H. , Yang Wei-Hsiung , Lillard James W. , Zhang Xingyi , Wang Lizhong , Liu Runhua
Published: April 2023

Figure S1: (Overexpression of CD24 mRNA in human PCa tissue based on analysis of three datasets); Figure S2: (Nuclear CD24 and p53 staining in human PCa cases); Figure S3: (The sequence-specific DNA binding sites of p53 in its target genes); Figure S4: (CD24-dependent inactivation of mutant p53 and cell cycle arrast in human LNCaP cells).
Table S4 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Authors: Kwiatkowski David J. , Choueiri Toni K. , Fay André P. , Rini Brian I. , Thorner Aaron R. , de Velasco Guillermo , Tyburczy Magdalena E. , Hamieh Lana , Albiges Laurence , Agarwal Neeraj , Ho Thai H. , Song Jiaxi , Pignon Jean-Christophe , Barrios Pablo M. , Michaelson M. Dror , Van Allen Eliezer M. , Krajewski Katherine M. , Porta Camillo , Pal Sumanta Kumar , Bellmunt Joaquim , McDermott David F. , Heng Daniel Y.C. , Gray Kathryn P. , Signoretti Sabina
Published: April 2023

Copy number status of mTOR pathway genes according to responder status
Table S3 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Authors: Kwiatkowski David J. , Choueiri Toni K. , Fay André P. , Rini Brian I. , Thorner Aaron R. , de Velasco Guillermo , Tyburczy Magdalena E. , Hamieh Lana , Albiges Laurence , Agarwal Neeraj , Ho Thai H. , Song Jiaxi , Pignon Jean-Christophe , Barrios Pablo M. , Michaelson M. Dror , Van Allen Eliezer M. , Krajewski Katherine M. , Porta Camillo , Pal Sumanta Kumar , Bellmunt Joaquim , McDermott David F. , Heng Daniel Y.C. , Gray Kathryn P. , Signoretti Sabina
Published: April 2023

Mutational status of non-mTOR pathway genes according to responder status
Table S2 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Authors: Kwiatkowski David J. , Choueiri Toni K. , Fay André P. , Rini Brian I. , Thorner Aaron R. , de Velasco Guillermo , Tyburczy Magdalena E. , Hamieh Lana , Albiges Laurence , Agarwal Neeraj , Ho Thai H. , Song Jiaxi , Pignon Jean-Christophe , Barrios Pablo M. , Michaelson M. Dror , Van Allen Eliezer M. , Krajewski Katherine M. , Porta Camillo , Pal Sumanta Kumar , Bellmunt Joaquim , McDermott David F. , Heng Daniel Y.C. , Gray Kathryn P. , Signoretti Sabina
Published: April 2023

List of all patients with complete information on mutations found and allele frequency
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Authors: Kwiatkowski David J. , Choueiri Toni K. , Fay André P. , Rini Brian I. , Thorner Aaron R. , de Velasco Guillermo , Tyburczy Magdalena E. , Hamieh Lana , Albiges Laurence , Agarwal Neeraj , Ho Thai H. , Song Jiaxi , Pignon Jean-Christophe , Barrios Pablo M. , Michaelson M. Dror , Van Allen Eliezer M. , Krajewski Katherine M. , Porta Camillo , Pal Sumanta Kumar , Bellmunt Joaquim , McDermott David F. , Heng Daniel Y.C. , Gray Kathryn P. , Signoretti Sabina
Published: April 2023

List of all patients with response status, survival status, age, sex, histology, drug treatment, and summary of mutation findings
Supplementary Methods and Figure legend from Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Authors: Sinha Sutapa , Boysen Justin , Nelson Michael , Secreto Charla , Warner Steven L. , Bearss David J. , Lesnick Connie , Shanafelt Tait D. , Kay Neil E. , Ghosh Asish K.
Published: April 2023

Supplementary Methods and Figure legend. This document contains supplementary methods and legend to the Supplementary Figure 1
Supplementary Figure S6 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Authors: Krepler Clemens , Xiao Min , Sproesser Katrin , Brafford Patricia A. , Shannan Batool , Beqiri Marilda , Liu Qin , Xu Wei , Garman Bradley , Nathanson Katherine L. , Xu Xiaowei , Karakousis Giorgos C. , Mills Gordon B. , Lu Yiling , Ahmed Tamer A. , Poulikakos Poulikos I. , Caponigro Giordano , Boehm Markus , Peters Malte , Schuchter Lynn M. , Weeraratna Ashani T. , Herlyn Meenhard
Published: April 2023

IHC staining of WM3965 PDX tumors treated with indicated compounds after 3 day of dosing and 4 hours post last dose for Ki67 (upper row) and cleaved caspase 3 (lower row).
Supplementary Table S2 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Authors: Gradishar William J. , Yardley Denise A. , Layman Rachel , Sparano Joseph A. , Chuang Ellen , Northfelt Donald W. , Schwartz Gary N. , Youssoufian Hagop , Tang Shande , Novosiadly Ruslan , Forest Amelie , Nguyen Tuan S. , Cosaert Jan , Grebennik Dmitri , Haluska Paul
Published: April 2023

The distributions of mRNA gene expression levels IGF-1R, Total IR, IR-A, and IR-B
Supplementary Table S1 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Authors: Gradishar William J. , Yardley Denise A. , Layman Rachel , Sparano Joseph A. , Chuang Ellen , Northfelt Donald W. , Schwartz Gary N. , Youssoufian Hagop , Tang Shande , Novosiadly Ruslan , Forest Amelie , Nguyen Tuan S. , Cosaert Jan , Grebennik Dmitri , Haluska Paul
Published: April 2023

Exploratory efficacy analysis (per-protocol population)
Supplementary Figure S2 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Authors: Krepler Clemens , Xiao Min , Sproesser Katrin , Brafford Patricia A. , Shannan Batool , Beqiri Marilda , Liu Qin , Xu Wei , Garman Bradley , Nathanson Katherine L. , Xu Xiaowei , Karakousis Giorgos C. , Mills Gordon B. , Lu Yiling , Ahmed Tamer A. , Poulikakos Poulikos I. , Caponigro Giordano , Boehm Markus , Peters Malte , Schuchter Lynn M. , Weeraratna Ashani T. , Herlyn Meenhard
Published: April 2023

H&E staining of all patients and PDX; MP1: first mouse passage; MP3+: min. of 3 and max. of 5 serial transplantations; on BRAFi: mice were chronically dosed with PLX4720-additive diet.
Supplementary Figure S1 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Authors: Gradishar William J. , Yardley Denise A. , Layman Rachel , Sparano Joseph A. , Chuang Ellen , Northfelt Donald W. , Schwartz Gary N. , Youssoufian Hagop , Tang Shande , Novosiadly Ruslan , Forest Amelie , Nguyen Tuan S. , Cosaert Jan , Grebennik Dmitri , Haluska Paul
Published: April 2023

Kaplan-Meier curves of PFS and OS in pooled group and arm A dichotomized by insulin receptor-A (IR-A) expression (high vs. low) using the 75th percentile of marker distribution as cutpoint.
Supplementary Figure S1 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Authors: Krepler Clemens , Xiao Min , Sproesser Katrin , Brafford Patricia A. , Shannan Batool , Beqiri Marilda , Liu Qin , Xu Wei , Garman Bradley , Nathanson Katherine L. , Xu Xiaowei , Karakousis Giorgos C. , Mills Gordon B. , Lu Yiling , Ahmed Tamer A. , Poulikakos Poulikos I. , Caponigro Giordano , Boehm Markus , Peters Malte , Schuchter Lynn M. , Weeraratna Ashani T. , Herlyn Meenhard
Published: April 2023

All growth curves of first implantation and subsequent expansions with and without continuous BRAF inhibitor (PLX4720) diet. Error bars are SEM.
Supplemental Table from Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Authors: Moon Edmund K. , Ranganathan Raghuveer , Eruslanov Evgeniy , Kim Soyeon , Newick Kheng , O'Brien Shaun , Lo Albert , Liu Xiaojun , Zhao Yangbing , Albelda Steven M.
Published: April 2023

Summary of publications describing tumor induced hypofunction of human tumor infiltrating lymphocytes.
Supplemental Table 2 from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Authors: de Leeuw Renée , Berman-Booty Lisa D. , Schiewer Matthew J. , Ciment Stephen J. , Den Robert B. , Dicker Adam P. , Kelly William K. , Trabulsi Edouard J. , Lallas Costas D. , Gomella Leonard G. , Knudsen Karen E.
Published: April 2023

Gene clusters corresponding with Figure 6A - LNCaP cells.
Supplemental Table 1 from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Authors: de Leeuw Renée , Berman-Booty Lisa D. , Schiewer Matthew J. , Ciment Stephen J. , Den Robert B. , Dicker Adam P. , Kelly William K. , Trabulsi Edouard J. , Lallas Costas D. , Gomella Leonard G. , Knudsen Karen E.
Published: April 2023

Gene clusters corresponding with Figure 6A - LNCaP cells.
Supplemental Figure 4 from Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Authors: Moon Edmund K. , Ranganathan Raghuveer , Eruslanov Evgeniy , Kim Soyeon , Newick Kheng , O'Brien Shaun , Lo Albert , Liu Xiaojun , Zhao Yangbing , Albelda Steven M.
Published: April 2023

Expression of inhibitory receptors on tumor vs. spleen infiltrating lymphocytes.
Supplemental Figure 2 from Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Authors: Moon Edmund K. , Ranganathan Raghuveer , Eruslanov Evgeniy , Kim Soyeon , Newick Kheng , O'Brien Shaun , Lo Albert , Liu Xiaojun , Zhao Yangbing , Albelda Steven M.
Published: April 2023

Co-expression of inhibitory receptors on tumor infiltrating lymphocytes.
Supplementary Figure 2 from Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
Authors: Chong Curtis R. , Bahcall Magda , Capelletti Marzia , Kosaka Takayuki , Ercan Dalia , Sim Taebo , Sholl Lynette M. , Nishino Mizuki , Johnson Bruce E. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Comparison of compound libraries reported in ROS1 kinase screens
Supplementary Figure 1 from Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
Authors: Chong Curtis R. , Bahcall Magda , Capelletti Marzia , Kosaka Takayuki , Ercan Dalia , Sim Taebo , Sholl Lynette M. , Nishino Mizuki , Johnson Bruce E. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Pathways targeted by the Dana-Farber Targeted Therapy Collection and clinical development status
Supplementary Figures S1-S6 and Figure Legends from Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and Its Nuclear Accumulation Suppresses Gastric Tumorigenesis
Authors: Cao Longlong , Zhou Jiechao , Zhang Junrong , Wu Sijin , Yang Xintao , Zhao Xin , Li Huifang , Luo Ming , Yu Qian , Lin Guangtan , Lin Huizhong , Xie Jianwei , Li Ping , Hu Xiaoqing , Zheng Chaohui , Bu Guojun , Zhang Yun-wu , Xu Huaxi , Yang Yongliang , Huang Changming , Zhang Jie
Published: April 2023

Supplementary Figures S1-S6 and Figure Legends. Figure S1. Western blotting and RT-PCR results depicting CDK5 expression levels from 171 patients. Figure S2. Immunofluorescence staining of CDK1, CDK2, CDK3, and CDK4 in gastric cells. Figure S3. Nuclear/cytoplasmic distribution of CDK5 during cell cycle activity in gastric cancer cells. Figure S4. Flow Cytometry assay for identification of synchronized gastric cancer cells. Figure S5. Gastric cancer cells overexpressing nuclear CDK5 or CDK5-KD cells exhibited a much retarded in vitro growth rate than control cells. Figure S6. NS-0011 induced the nuclear translocation of CDK5 in MGC-803 cells by dose dependent.
Figure S8 from β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer
Authors: San Millán Coral , Soldevilla Beatriz , Martín Paloma , Gil-Calderón Beatriz , Compte Marta , Pérez-Sacristán Belén , Donoso Encarnación , Peña Cristina , Romero Jesús , Granado-Lorencio Fernando , Bonilla Félix , Domínguez Gemma
Published: April 2023

Figure S8. Representative images of the mice lymphocytes DNA after the Comet Assay. Differences between head and tail sizes indicate the calculated basal DNA damage (A: vehicle, B: Î²-cryptoxanthin) and the interstrand crosslinks induced by the different treatments (C: vehicle, D: Î²-cryptoxanthin, E: vehicle and oxaliplatin, F: oxaliplatin and Î²-cryptoxanthin).
Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer
Authors: Ferrarotto Renata , Goonatilake Ruchitha , Young Yoo Suk , Tong Pan , Giri Uma , Peng Shaohua , Minna John , Girard Luc , Wang Yuehong , Wang Liguang , Li Lerong , Diao Lixia , Peng David H. , Gibbons Don L. , Glisson Bonnie S. , Heymach John V. , Wang Jing , Byers Lauren A. , Johnson Faye M.
Published: April 2023

Supplemental Tables and Supplementary Figure Legends
Figure S2-S3 from β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer
Authors: San Millán Coral , Soldevilla Beatriz , Martín Paloma , Gil-Calderón Beatriz , Compte Marta , Pérez-Sacristán Belén , Donoso Encarnación , Peña Cristina , Romero Jesús , Granado-Lorencio Fernando , Bonilla Félix , Domínguez Gemma
Published: April 2023

Figure S2-S3. Figure S2. Oxaliplatin concentration-response graphs for HCT116, SW480-ADH and SW1417 cells. Cells were treated with 0, 10, 25, 50, 100 and 150 Î¼M oxaliplatin and viability rates were evaluated by the MTT assay. Mean {plus minus} standard deviation of at least three independent experiments is represented. Figure S3. Viability quantified by MTT assay was assessed in HCT116 after treatment with different concentrations of (A) Î²-cryptoxanthin, (B) oxaliplatin and, (C) with four different combined regimens. Combination Index (CI) values for each combined treatment are shown and were calculated using the Calcusyn software (Biosof). CI values between 0.3-0.7 indicate synergism. Mean {plus minus} standard deviation of at least three independent experiments is represented.
Supplemental Figure 3 from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer
Authors: Ferrarotto Renata , Goonatilake Ruchitha , Young Yoo Suk , Tong Pan , Giri Uma , Peng Shaohua , Minna John , Girard Luc , Wang Yuehong , Wang Liguang , Li Lerong , Diao Lixia , Peng David H. , Gibbons Don L. , Glisson Bonnie S. , Heymach John V. , Wang Jing , Byers Lauren A. , Johnson Faye M.
Published: April 2023

Dose-response curves for NSCLC cell lines and treatments from Fig. 5 on a linear scale.
Supplementary Figures 1-4 from ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells
Authors: Powell Katelyn , Semaan Louie , Conley-LaComb M. Katie , Asangani Irfan , Wu Yi-Mi , Ginsburg Kevin B. , Williams Julia , Squire Jeremy A. , Maddipati Krishna R. , Cher Michael L. , Chinni Sreenivasa R.
Published: April 2023

Supplementary Figures 1-4. Supplementary Figure 1. Characterization of lentivirus mediated ERG overexpression/knockdown Supplementary Figure 2. Mass Spectrometric analysis of androgens Supplementary Figure 3. AR nuclear translocation and characterization of ERG and AKR1C3 knockdown Supplementary Figure 4. Oncomine and Geo database analysis
Supplemental Materials and Methods from CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Authors: Olanich Mary E. , Sun Wenyue , Hewitt Stephen M. , Abdullaev Zied , Pack Svetlana D. , Barr Frederic G.
Published: April 2023

Supplemental Materials and Methods
Supplemental Figure S2 from Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression
Authors: Brooks Samira A. , Khandani Amir H. , Fielding Julia R. , Lin Weili , Sills Tiffany , Lee Yueh , Arreola Alexandra , Milowsky Mathew I. , Wallen Eric M. , Woods Michael E. , Smith Angie B. , Nielsen Mathew E. , Parker Joel S. , Lalush David S. , Rathmell W. Kimryn
Published: April 2023

ccRCC subtypes have intra-tumor genomic similarities.
Supplemental Methods and Tables from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Authors: Benito Juliana , Ramirez Marc S. , Millward Niki Zacharias , Velez Juliana , Harutyunyan Karine G. , Lu Hongbo , Shi Yue-xi , Matre Polina , Jacamo Rodrigo , Ma Helen , Konoplev Sergej , McQueen Teresa , Volgin Andrei , Protopopova Marina , Mu Hong , Lee Jaehyuk , Bhattacharya Pratip K. , Marszalek Joseph R. , Davis R. Eric , Bankson James A. , Cortes Jorge E. , Hart Charles P. , Andreeff Michael , Konopleva Marina
Published: April 2023

Supplemental Methods and Tables 1) mRNA Hybridization and Gene-expression Profiling. 2) Gene expression analysis by Nanostring technology. 3) Hyperpolarized Magnetic Resonance Spectroscopy. 4) In Vitro 1-13C Pyruvic Acid Feeding Studies and High Resolution Nuclear Magnetic Resonance (NMR) Experiments 5) Three-dimensional spheroids 6) Murine tumor models 7) Immunohistochemistry Supplementary Table S1. Cell line characteristics Supplementary Table S2. Patient characteristics Supplemental Table S3. List of upregulated DEPs in hypoxia. Supplemental Table S4. 1-13C pyruvate uptake and 1-13C lactate production in cell culture. Supplemental Table S5. TH-302 cytotoxic activity against leukemia cell lines
Supplemental Figure 1 from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
Authors: Galimberti Sara , Luminari Stefano , Ciabatti Elena , Grassi Susanna , Guerrini Francesca , Dondi Alessandra , Marcheselli Luigi , Ladetto Marco , Piccaluga Pier Paolo , Gazzola Anna , Mannu Claudia , Monitillo Luigia , Mantoan Barbara , Del Giudice Ilaria , Della Starza Irene , Cavalli Marzia , Arcaini Luca , Tucci Alessandra , Palumbo Giuseppe Alberto , Rigacci Luigi , Pulsoni Alessandro , Vitolo Umberto , Boccomini Carola , Vallisa Daniele , Bertoldero Giovanni , Gaidano Gianluca , Musto Pellegrino , Petrini Mario , Federico Massimo
Published: April 2023

CONSORT diagram of the study.
Supplemental Table III from Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Authors: Donnem Tom , Hald Sigurd M. , Paulsen Erna-Elise , Richardsen Elin , Al-Saad Samer , Kilvaer Thomas K. , Brustugun Odd Terje , Helland Aslaug , Lund-Iversen Marius , Poehl Mette , Olsen Karen Ege , Ditzel Henrik J. , Hansen Olfred , Al-Shibli Khalid , Kiselev Yury , Sandanger Torkjel M. , Andersen Sigve , Pezzella Francesco , Bremnes Roy M. , Busund Lill-Tove
Published: April 2023

Supplemental Table III. Prognostic clinicopathologic variables as predictors for Overall Survival in 797 NSCLS (univariate analyses,log-rank test)
Supplemental Table I from Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Authors: Donnem Tom , Hald Sigurd M. , Paulsen Erna-Elise , Richardsen Elin , Al-Saad Samer , Kilvaer Thomas K. , Brustugun Odd Terje , Helland Aslaug , Lund-Iversen Marius , Poehl Mette , Olsen Karen Ege , Ditzel Henrik J. , Hansen Olfred , Al-Shibli Khalid , Kiselev Yury , Sandanger Torkjel M. , Andersen Sigve , Pezzella Francesco , Bremnes Roy M. , Busund Lill-Tove
Published: April 2023

Supplemental Table I. Prognostic clinicopathologic variables as predictors for DSS in 797 NSCLS (univariate analyses,log-rank test)
Supplemental Figure legends from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
Authors: Song Shumei , Honjo Soichiro , Jin Jiankang , Chang Shih-Shin , Scott Ailing W. , Chen Qiongrong , Kalhor Neda , Correa Arlene M. , Hofstetter Wayne L. , Albarracin Constance T. , Wu Tsung-Teh , Johnson Randy L. , Hung Mien-Chie , Ajani Jaffer A.
Published: April 2023

Supplemental Figure legends. Figure legends for Supplemental Figure 1-4
Supplementary Tables 1-2 from Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Authors: Ock Chan-Young , Lee Keun-Wook , Kim Jin Won , Kim Jin-Soo , Kim Tae-Yong , Lee Kyung-Hun , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Kim Woo Ho , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

Supplementary Tables 1-2. Table S1. HER2/CEP17 ratio and HER2 gene copy number by HER2 IHC; Table S2: Univariateand multivariate Cox analysis of overall survival
Supplemental Figure 1 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
Authors: Song Shumei , Honjo Soichiro , Jin Jiankang , Chang Shih-Shin , Scott Ailing W. , Chen Qiongrong , Kalhor Neda , Correa Arlene M. , Hofstetter Wayne L. , Albarracin Constance T. , Wu Tsung-Teh , Johnson Randy L. , Hung Mien-Chie , Ajani Jaffer A.
Published: April 2023

Supplemental Figure 1. YAP mediates constitutive chemoresistance in EC cells
Supplementary Table S3 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Authors: Shahbazi Jeyran , Liu Pei Y. , Atmadibrata Bernard , Bradner James E. , Marshall Glenn M. , Lock Richard B. , Liu Tao
Published: April 2023

The top 35 genes most dramatically down-regulated by JQ1 and panobinostat combination therapy.
Supplementary figure legend from Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Authors: Yan Pu , Klingbiel Dirk , Saridaki Zenia , Ceppa Paola , Curto Monica , McKee Thomas Alexander , Roth Arnaud , Tejpar Sabine , Delorenzi Mauro , Bosman Fredrik T. , Fiocca Roberto
Published: April 2023

Legends for supplementary figures 1 and 2
Supplementary Figure S3 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Authors: Shahbazi Jeyran , Liu Pei Y. , Atmadibrata Bernard , Bradner James E. , Marshall Glenn M. , Lock Richard B. , Liu Tao
Published: April 2023

Combination therapy with JQ1 and panobinostat synergistically reduces neuroblastoma cell viability.
Supplementary Figure S1 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Authors: Shahbazi Jeyran , Liu Pei Y. , Atmadibrata Bernard , Bradner James E. , Marshall Glenn M. , Lock Richard B. , Liu Tao
Published: April 2023

The BET bromodomain proteins BRD3 and BRD4 induce N-Myc expression, but do not function synergistically.
Supplementary Table 1 from Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression
Authors: Satelli Arun , Mitra Abhisek , Brownlee Zachary , Xia Xueqing , Bellister Seth , Overman Michael J. , Kopetz Scott , Ellis Lee M. , Meng Qing H. , Li Shulin
Published: April 2023

Supplementary Table 1. Clinical Parameters in patients
Supplementary Figure S1 from Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Authors: Wu Lixian , Yu Jing , Chen Ruijia , Liu Yang , Lou Liguang , Wu Ying , Huang Lisen , Fan Yingjuan , Gao Pinzhang , Huang Meijuan , Wu Yong , Chen Yuanzhong , Xu Jianhua
Published: April 2023

Supplementary Figure S1. C086 induces apoptosis in imatinib-sensitive and -resistant CML cells.
Supplementary Table 5 from Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Authors: Vathipadiekal Vinod , Wang Victoria , Wei Wei , Waldron Levi , Drapkin Ronny , Gillette Michael , Skates Steven , Birrer Michael
Published: April 2023

Supplementary Table 5. Non-pathway associated probesets up-regulated in cancer as compared to both normal fallopian and ovarian surface epithelium.
Supplemental Figure S3 from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
Authors: Bowers Jacob S. , Nelson Michelle H. , Kundimi Sreenath , Bailey Stefanie R. , Huff Logan W. , Schwartz Kristina M. , Cole David J. , Rubinstein Mark P. , Paulos Chrystal M.
Published: April 2023

Supplemental Figure S3. Effect of TBI on co-stimulatory ligand expression on myeloid cells in the tumor. A-B, Co-stimulatory ligand expression of CD11b+Ly6ChiLy6Glo MDSC-M (A), and CD11b+Ly6CCmidLy6Ghi MDSC-G (B) in the spleens of mice receiving 0, 5, or 9 Gy irradiation 1 day prior to spleen harvest; n=3 mice per group; * = p<0.05, ** = p<0.01, *** = p<0.001, two tail t-test, error bars represent standard error.
Supplementary Tables 1-4 from Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Authors: Mok Tony , Wu Yi-Long , Lee Jin Soo , Yu Chong-Jen , Sriuranpong Virote , Sandoval-Tan Jennifer , Ladrera Guia , Thongprasert Sumitra , Srimuninnimit Vichien , Liao Meilin , Zhu Yunzhong , Zhou Caicun , Fuerte Fatima , Margono Benjamin , Wen Wei , Tsai Julie , Truman Matt , Klughammer Barbara , Shames David S. , Wu Lin
Published: April 2023

Supplementary Tables 1-4. Supplementary Table 1. Concordance, sensitivity, specificity, positive and negative predictive values of tissue and cfDNA tests (n=238) by EGFR mutation type Supplementary Table 2: EGFR mutation type Supplementary Table 3: EGFR mutation type in matched tumor and plasma samples Supplementary Table 4: Baseline characteristics in EGFR mut+ patients with only blood-based samples
Supplemental Table 3 from New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice
Authors: Kisiel John B. , Raimondo Massimo , Taylor William R. , Yab Tracy C. , Mahoney Douglas W. , Sun Zhifu , Middha Sumit , Baheti Saurabh , Zou Hongzhi , Smyrk Thomas C. , Boardman Lisa A. , Petersen Gloria M. , Ahlquist David A.
Published: April 2023

Supplemental Table 3. Function and cancer biology associations of candidates